WO1999047639A3 - Staphylococcus aureus genes and polypeptides - Google Patents

Staphylococcus aureus genes and polypeptides Download PDF

Info

Publication number
WO1999047639A3
WO1999047639A3 PCT/US1999/005976 US9905976W WO9947639A3 WO 1999047639 A3 WO1999047639 A3 WO 1999047639A3 US 9905976 W US9905976 W US 9905976W WO 9947639 A3 WO9947639 A3 WO 9947639A3
Authority
WO
WIPO (PCT)
Prior art keywords
polypeptides
relates
staphylococcus aureus
antibodies
present
Prior art date
Application number
PCT/US1999/005976
Other languages
French (fr)
Other versions
WO1999047639A2 (en
Inventor
Andrew J G Simpson
Gil H Choi
Original Assignee
Human Genome Sciences Inc
Ludwig Inst Cancer Res
Andrew J G Simpson
Gil H Choi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Human Genome Sciences Inc, Ludwig Inst Cancer Res, Andrew J G Simpson, Gil H Choi filed Critical Human Genome Sciences Inc
Priority to AU33573/99A priority Critical patent/AU3357399A/en
Publication of WO1999047639A2 publication Critical patent/WO1999047639A2/en
Publication of WO1999047639A3 publication Critical patent/WO1999047639A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to 11 novel genes from S. aureus and the polypeptides they encode. Also provided are vectors, host cells, antibodies and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of S. aureus polypeptide activity. The invention additionally relates to diagnostic methods for detecting Staphylococcus nucleic acids, polypeptides and antibodies in a biological sample. The present invention further relates to novel vaccines for the prevention or attenuation of infection by Staphylococcus.
PCT/US1999/005976 1998-03-20 1999-03-19 Staphylococcus aureus genes and polypeptides WO1999047639A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU33573/99A AU3357399A (en) 1998-03-20 1999-03-19 (staphylococcus) aureus genes and polypeptides

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US7868298P 1998-03-20 1998-03-20
US60/078,682 1998-03-20
US8029698P 1998-04-01 1998-04-01
US60/080,296 1998-04-01
US8467498P 1998-05-07 1998-05-07
US60/084,674 1998-05-07

Publications (2)

Publication Number Publication Date
WO1999047639A2 WO1999047639A2 (en) 1999-09-23
WO1999047639A3 true WO1999047639A3 (en) 2001-08-23

Family

ID=27373335

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/US1999/006199 WO1999047662A1 (en) 1998-03-20 1999-03-18 Staphylococcus aureus genes and polypeptides
PCT/US1999/005976 WO1999047639A2 (en) 1998-03-20 1999-03-19 Staphylococcus aureus genes and polypeptides

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/US1999/006199 WO1999047662A1 (en) 1998-03-20 1999-03-18 Staphylococcus aureus genes and polypeptides

Country Status (6)

Country Link
US (3) US6521441B1 (en)
EP (1) EP1064366A1 (en)
JP (1) JP2002516068A (en)
AU (2) AU3108399A (en)
CA (1) CA2323724A1 (en)
WO (2) WO1999047662A1 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6356845B1 (en) 1999-08-04 2002-03-12 Pharmacia & Upjohn Company Crystallization and structure determination of Staphylococcus aureus UDP-N-acetylenolpyruvylglucosamine reductase (S. aureus MurB)
US6689595B1 (en) 1999-08-04 2004-02-10 Pharmacia & Upjohn Company Crystallization and structure determination of Staphylococcus aureus thymidylate kinase
AU2001233099A1 (en) 2000-01-31 2001-08-07 Pharmacia And Upjohn Company Crystallization and structure determination of staphylococcus aureus nad synthetase
US6864080B2 (en) 2000-06-30 2005-03-08 Pharmacia & Upjohn Company Crystallization and structure of Staphylococcus aureus peptide deformylase
US20020072105A1 (en) * 2000-08-17 2002-06-13 Benson Timothy E. Crystallization and structure determination of FemA and FemA-like proteins
WO2003087352A2 (en) * 2002-04-09 2003-10-23 Affinium Pharmaceuticals, Inc. Enolase polypeptides and structures
EP1499191B1 (en) * 2002-04-15 2012-05-09 Washington University in St. Louis Regulated attenuation of live vaccines to enhance cross protective immunogenicity
CA2956645A1 (en) * 2003-07-12 2005-03-31 David A. Goldberg Sensitive and rapid biodetection
US8729013B2 (en) 2004-08-26 2014-05-20 The University Of Western Ontario Methods of inhibiting staphylobactin-mediated iron uptake in S. aureus
KR20070057864A (en) 2004-08-26 2007-06-07 더 유니버시티 오브 웨스턴 온타리오 Pharmaceutical compositions comprising inhibitors of iron transport, and method of identifying iron transport inhibitors, fn staphylococcus aureus
US7384817B2 (en) * 2005-05-13 2008-06-10 Sandisk Corporation Method of assembling semiconductor devices with LEDs
EP2150625B1 (en) 2007-04-19 2013-03-20 Molecular Detection Inc. Methods, compositions and kits for detection and analysis of antibiotic-resistant bacteria
GB0823550D0 (en) * 2008-12-24 2009-01-28 Kinasource Ltd Peptide tag and uses thereof
WO2012065034A1 (en) * 2010-11-12 2012-05-18 Merck Sharp & Dohme Corp. Enolase peptide conjugate vaccines against staphylococcus aureus
US20140186386A1 (en) * 2011-06-06 2014-07-03 Jeffrey Weiser Methods for preventing and treating staphylococcus aureus colonization, infection, and disease
EP2773370A4 (en) 2011-10-31 2016-09-28 Merck Sharp & Dohme Protective vaccine based on staphylococcus aureus sa2451 protein
US9376487B2 (en) 2012-07-10 2016-06-28 Merck Sharp & Dohme Corp. Protective vaccine based on Staphylococcus aureus SA2493 protein

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8904762D0 (en) * 1989-03-02 1989-04-12 Glaxo Group Ltd Biological process
IL109410A0 (en) 1993-04-30 1994-07-31 Ell Lilly & Company Fema gene of staphylococcus epidermidis, fema protein, and vectors and microorganisms comprising the fema gene
US6748101B1 (en) * 1995-05-02 2004-06-08 Cummins-Allison Corp. Automatic currency processing system
US5632786A (en) * 1995-09-14 1997-05-27 Amoco Corporation Process and fuel for spark ignition engines
US6593114B1 (en) * 1996-01-05 2003-07-15 Human Genome Sciences, Inc. Staphylococcus aureus polynucleotides and sequences

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE GENBANK [online] 1 January 1997 (1997-01-01), SUGAI ET AL.: "Epr, which encodes glycylglycine endopeptidase resistance, is homologous to femAB and affects serine content of pepptidoglycan cross bridges in Staphylococcus capitis and Staphylococcus aureus", XP002945334, accession no. EMBL-15 Database accession no. AB000222 *
DATABASE GENBANK [online] 30 September 1991 (1991-09-30), BERGER-BAECHI ET AL.: "FemA, a host-mediated factor essential for methicillin resistance in Staphyloccus", XP002945335, accession no. EMBL Database accession no. X17688 *

Also Published As

Publication number Publication date
US20050053995A1 (en) 2005-03-10
JP2002516068A (en) 2002-06-04
AU3357399A (en) 1999-10-11
US6521441B1 (en) 2003-02-18
CA2323724A1 (en) 1999-09-23
US6821754B2 (en) 2004-11-23
WO1999047639A2 (en) 1999-09-23
US20030153733A1 (en) 2003-08-14
WO1999047662A1 (en) 1999-09-23
EP1064366A1 (en) 2001-01-03
AU3108399A (en) 1999-10-11

Similar Documents

Publication Publication Date Title
WO1999047639A3 (en) Staphylococcus aureus genes and polypeptides
WO1998050554A3 (en) Enterococcus faecalis polynucleotides and polypeptides
EP1770164A3 (en) Streptococcus pneumoniae antigens and vaccines
WO1998031818A3 (en) Tace-like and matrilysin-like polypeptides
WO2000012678A3 (en) Staphylococcus aureus genes and polypeptides
CA2239692A1 (en) Diagnosis and treatment of aur-1 and/or aur-2 related disorders
CA2294516A1 (en) Ikk-.beta. proteins, nucleic acids and methods
ATE464067T1 (en) CONNECTIVE TISSUE GROWTH FACTOR (CTGF)
WO1999064592A3 (en) Green fluorescent proteins for measuring the ph of a biological sample
WO1999037788A3 (en) Diagnosis and treatment of aur1 and/or aur2 related disorders
EP0397633A3 (en) Fibronectin binding protein as well as its preparation
CA2270868A1 (en) Method to detect ige
DE60026332D1 (en) DIAGNOSIS OF DOMESTIC SPRUE / CELIAC DISEASE WITH THE HELP OF GLIADINE PITOPENES
CA2295999A1 (en) Nik proteins, nucleic acids and methods
EP2298899A3 (en) CRSP proteins (cysteine-rich secreted proteins), nucleic acid molecules encoding them and uses therefor
WO1999009186A3 (en) Polypeptide nucleic sequences exported from mycobacteria, vectors comprising same and uses for diagnosing and preventing tuberculosis
CA2294566A1 (en) Ikk-.alpha. proteins, nucleic acids and methods
WO1998011226A3 (en) Mammalian chemokines, related reagents
WO2001044809A3 (en) Evaluation of biological agents in living target cells
WO2000019988A8 (en) NOVEL Th2-SPECIFIC MOLECULES AND USES THEREOF
WO1994026891A3 (en) Purified mammalian flt3 ligands and agonists and antagonists thereof
EP1136547A3 (en) Adamts polypeptides, nucleic acids encoding them, and uses thereof
WO2001009328A8 (en) 15571, a novel gpcr-like molecule of the secretin-like family and uses thereof
WO2001025432A3 (en) Histamine receptor
EP0960937A4 (en) Novel semaphorin gene: semaphorin y

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase